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ABSTRACT 
OBJECTIVE. To use electronic health records to describe the use of cefovecin (Convenia; 
Zoetis UK), a third generation long-acting injectable antimicrobial, in a UK population of 
cats attending first opinion practice and to compare the use of Convenia to the licenced uses 
described on the UK Convenia datasheet.  
METHODS. Data were obtained as an excel database from the Small Animal Veterinary 
Surveillance Network for all feline consultations containing the word Convenia and/or 
cefovecin from 1st September 2012 to 23rd September 2013 inclusive. Entries were classified 
according to body system treated, confirmation or suspicion of an abscess, evidence of 
microbiological evaluation being performed, any concurrent therapies given, and whether any 
reason was given for use of Convenia over alternative antimicrobials. Data were exported to 
IBM SPSS Statistics and descriptive analysis performed.  
RESULTS. In total, 1,148 entries were analysed. The most common body system treated was 
skin in 553 (48.2%) entries, then urinary (157, 13.7%) and respiratory (112, 9.8%). 
Microbiological evaluation was recorded in 193 (16.8%) entries, with visible purulent 
material most commonly cited in 147 (12.8%) entries. A reason for prescribing Convenia 
over alternative antimicrobials was given in 138 (12%) entries; the most cited was an 
inability to orally medicate the cat in 77 (55.8%) of these entries. Excluding 131 entries 
where no body system or multiple body systems were described, the use of Convenia 
complied with a licenced use in the UK datasheet in 710 (69.8%) of 1017 entries.   
CONCLUSION. Most administrations were licensed uses however most entries did not 
describe any microbiological evaluation nor a reason for prescribing Convenia over 
alternative antimicrobials. Further education of the public and the veterinary profession is 
needed to promote antimicrobial stewardship in the UK. Health records provide a valuable 
tool to monitor both locally and at scale the use of important therapeutics like antimicrobials. 
Information relevant to decision making should be recorded in individual animal health 
records. 
INTRODUCTION  
Antimicrobials can be classed according to the microorganism they are acting against and can 
include antibiotics, antifungals and antiseptics. In the UK all veterinary antibiotics are 
prescription-only medicines (POM-V); therefore the responsibility for and control of 
antibiotic use rests with the prescribing veterinarian1. In this study, antibiotics are referred to 
by the more widely used term antimicrobials.  
Antimicrobial resistance (AMR) is a global health concern in humans and animals2. There is 
much interest in determining ways to reduce AMR by advocating responsible veterinary 
antibiotic use including projects such as the Small Animal Medicine Society (SAMSoc) and 
British Small Animal Veterinary Association (BSAVA) Antibiotic Usage Guidelines3, and 
the Federation of European Companion Animal Veterinary Associations (FECAVA) 
European Antibiotic Use Guidelines4. In the UK around half of practices are members of the 
Royal College of Veterinary Surgeons Practice Standards Scheme. A component of this 
Scheme requires practices to demonstrate they use antimicrobials responsibly and are 
accountable for the choices made in such use5. One way to demonstrate this is to have local 
antimicrobial policies and/or use set protocols for treatment of common diseases and promote 
use of first line, licenced treatment choices. Notwithstanding this guidance, the use of written 
antimicrobial usage protocols is limited in general veterinary practice6 although recent 
awareness may have increased their usage7. 
Whether there is a genuine cause and effect of veterinary antimicrobial use and AMR in 
people is a contentious and complex issue, but at a basic level veterinarians have a 
professional responsibility to reduce AMR. This can be achieved through better 
understanding of appropriate antimicrobial use. 
Cefovecin (Convenia; Zoetis UK) is a long-acting third generation cephalosporin injectable 
antibiotic, widely used in cats6. Convenia is the only cefovecin available for use in small 
animals in the UK8. In human medicine, third generation cephalosporins are classed as 
‘Critically Important Antimicrobials’9. It is accepted that reducing use of this class of drug 
conforms to antimicrobial stewardship10 especially if adopting a ‘One Health’ approach with 
co-ordinated prudent use of antimicrobials in both human and veterinary medicine. 
In the UK, Convenia is licenced for use in cats for the treatment of skin and soft tissue 
abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., 
Bacteroides spp., Prevotella oralis, β haemolytic Streptococci and/or Staphylococcus 
pseudointermedius and for treatment of urinary tract infections (UTIs) associated with 
Escherichia coli. A single subcutaneous dose of 8.0 mg/kg Convenia has a 14 day duration of 
activity8, currently the only injectable veterinary antimicrobial in the UK to provide more 
than 48 hours of action. Convenia is therefore unique in providing guaranteed compliance 
alongside broad spectrum, long-acting activity.   
Data on the use of antimicrobials are available through surveillance systems such as the 
Small Animal Veterinary Surveillance Network (SAVSNET), a scheme established in 2008, 
becoming a joint venture between BSAVA and the University of Liverpool. SAVSNET 
receives routine downloads of diagnostic test results from commercial diagnostic laboratories 
and collects electronic health records in real time from veterinary practice consultations using 
a compatible version of practice management software (Premvet, Robovet and Teleos), 
throughout the UK, for the purposes of monitoring diseases. SAVSNET makes data available 
for research and improving public awareness of small animal diseases and prevention11. 
Clients of participating practices can opt out of data collection and are informed of the 
scheme through waiting room display information12, 13.  
This study describes the use of cefovecin (Convenia; Zoetis UK) in a population of cats in 
first opinion practice in the UK as recorded in electronic health records obtained from 
SAVSNET, and compares the use of Convenia to the licenced uses described on the UK 
Convenia datasheet. 
 
MATERIALS AND METHODS 
Data were obtained as an excel database from SAVSNET for all feline consultations or 
entries containing the word Convenia and/or cefovecin in the clinical notes from 11 
veterinary practices (total of 21 premises) from 1st September 2012 to 23rd September 2013 
inclusive. Each case entry and individual animal were given an anonymous unique number by 
SAVSNET and had the following variables recorded for the study: signalment (age, sex, 
neuter status), breed (classified as purebred or crossbreed) and weight (recorded or manually 
extracted from clinical notes). 
Duplicate case entries at an animal level, i.e. multiple visits for the same animal, and entries 
found not to have described Convenia administration were removed. Examples of entries 
omitted due to non-administration of Convenia contained text such as ‘give Convenia if 
struggle to tablet’ or ‘due Convenia next week’ in the clinical notes.  
The dose of Convenia given was calculated from volume of Convenia administered and cat’s 
weight, where such information was available in the clinical notes or recorded as tabulated 
data in the case of cat’s weight. All valid entries were manually classified using information 
in the clinical notes into the body system being treated, namely skin (including cat bite 
abscesses), urinary, respiratory, cardiovascular, ocular, oral, gastrointestinal (including liver 
and pancreas), musculoskeletal, neurological, unclassified (if it was unclear which body 
system was being treated with Convenia due to lack of information in clinical notes) or 
multiple (if more than one body system was described and it was unclear which primary body 
system was being treated with Convenia).  
The clinical notes were used to determine if evidence of an abscess was confirmed or 
suspected and defined by body system affected e.g. skin, oral (teeth), musculoskeletal, ocular, 
multiple (if more than one body system affected) or unclassified if abscessed body system 
could not be defined.  
Additional information extracted manually from the clinical notes included temperature if 
recorded, whether any type of microbiological evaluation was recorded (comprising 
observation of purulent material and whether urinalysis, cytology or culture and sensitivity 
(C&S) were performed), and whether concurrent therapies were given. If a reason was cited 
for use of Convenia over alternative antimicrobials then this was recorded e.g. ‘inability to 
medicate orally’ or ‘cat is a stray’. 
The clinical notes were analysed by two co-authors (SB and VB) to control experimenter’s 
potential bias. Entries were double checked by each co-author performing the analysis to 
ensure agreement. 
To assess ages of cats with feline lower urinary tract disease (FLUTD) believed to be 
associated with UTIs, the ages of cats in the urinary body system entries were also examined 
separately.  
All data were exported into IBM SPSS Statistics and descriptive analysis performed. Non-
normally distributed data were described using range and median. The uses of Convenia 
described were compared to licenced uses on the UK Convenia datasheet8. 
 
RESULTS 
Of 1,489 total entries, 297 duplicate entries and 44 non-Convenia entries were excluded, 
leaving 1,148 entries for analysis.  
The median age of the cat population assessed was 9.1 years, range 0.1 to 23.2 years. There 
were 574 (50%) males, 529 (46.1%) females and 45 (3.9%) cats of unknown sex. Of males, 
504 (87.8%) were neutered and 70 (12.2%) entire. Of females, 476 (90.0%) were neutered 
and 53 (10.0%) entire. Forty-five entries (3.9%) had no recorded neuter status. Entries 
comprised 999 (87%) crossbreeds, 121 (10.6%) purebred and 28 (2.4%) cats where breed was 
not recorded. Weight was recorded in 967 (84.2%) entries; median weight was 4.18 kg, range 
1.74 to 9.05 kg.  
The median dose of Convenia used was 8.0 mg/kg, range 3.5 – 21.5 mg/kg. Extreme 
variation in dose was caused by weights recorded on the practice management software that 
may not have been current or correct either due to age change i.e. a kitten weight recorded 
and now an adult cat or extreme weight gain or weight loss that had not been recorded. 
Examples include a 15-month old cat that had a recorded weight of 1.86 kg from the practice 
management system that was given 0.5 ml Convenia (21.5 mg/kg) and an eight year old cat 
that had a recorded weight of 6.9 kg on the practice management system that was given 0.3 
ml Convenia (3.5 mg/kg).  
The most common body system treated (Table 1) was skin in 553 (48.2%) entries, followed 
by urinary in 157 (13.7%) entries and respiratory in 112 (9.8%) entries. There were 103 
(9.0%) entries unclassified for body system treated due to lack of information in clinical 
notes.  
There was evidence of a confirmed or suspected abscess, based on the clinical notes, in 231 
(20.1%) entries; 199 (86.2%) of these were classified as ‘skin’ with respect to body system 
affected. The remaining confirmed or suspected abscesses were classified as either oral 
(associated with teeth; 14 entries, 6.1%), musculoskeletal (10 entries, 4.3%), multiple (five 
entries, 2.2%), ocular (two entries, 0.9%) and one (0.4%) unclassified due to lack of 
information.  
Temperature was recorded in 327 (28.5%) entries; 106 of these (32.4%) were elevated at 
greater than 38.9˚C14. 
Some form of microbiological evaluation was recorded in 193 (16.8%) of 1,148 entries. The 
most cited evaluation was visible purulent material in 147 (12.8%) entries. Urinalysis with 
dipstick only was described in 22 (1.9%) entries, followed by urine sediment examination 
(negative for bacteria) in 11 (1%) and one entry where urine sediment results were unknown. 
Urinalysis was recommended in nine (0.8%) entries but not performed at the time of 
Convenia administration, and one entry noted unsuccessful cystocentesis. Five entries (0.4%) 
had other cytology examinations performed (excluding urine sediment examination) that 
were positive for bacteria and one other cytology that was negative for bacteria. Only five 
(0.4%) of the 1,148 entries indicated in clinical notes that samples were taken for bacterial 
C&S. One of these entries comprised a vet taking a swab to be submitted only if there was no 
post-treatment improvement; the remaining four entries had C&S performed and Convenia 
prescribed at the same time, whilst the vet awaited results. In 14 of the 1,148 entries (1.2%) 
the owner declined investigations for microbiological evaluation. 
Of 1,148 entries, 525 (45.7%) had concurrent non-steroidal anti-inflammatory drug 
treatment; of these 489 (93.1%) had injectable or oral (or a combination of both) meloxicam 
with Metacam (Boehringer Ingelheim UK). Of 1,148 entries, 262 (22.8%) had concurrent 
steroid treatment; 99 (37.8%) of these had methylprednisolone acetate (Depo-Medrone V; 
Zoetis UK) and concurrent antimicrobials were used in 79 (6.9%) of total entries, e.g. fusidic 
acid (ocular, aural or topical) in 39 (49.4%) of these entries, clindamycin in 11 (13.9%), 
chloramphenicol (ocular) in 7 (8.9%) and clavulanic-potentiated amoxicillin in 5 (6.3%) 
entries. 
A reason for prescribing Convenia over alternative antimicrobials was given in clinical notes 
of 138 (12%) entries; the most cited reason was inability to orally medicate in 77 (55.8%) of 
these entries; other reasons included the cat being a stray (12 entries), the owner being away 
or the cat going into a cattery (11 entries), or the owner saying Convenia had worked 
previously (four entries). 
With respect to the 157 urinary body system entries only; urinalysis using only a dipstick was 
described in 22 (14.9%) entries, urine cytology was performed in 12 (7.6%) entries; 11 being 
negative for bacteria. Nine (5.7%) urinary entries recommended that urinalysis be done 
despite prescribing Convenia at the same time. Assessment of age in urinary body system 
entries revealed that 78 (49.7%) entries were less than ten years of age. 
To accurately assess compliance with the UK licenced uses on the UK Convenia datasheet, 
103 (9%) entries were excluded because no body system was described in clinical notes; 28 
(2.4%) were excluded because of the ‘multiple’ classification for body system, where it was 
not possible to infer the primary system of treatment and accordingly whether this may have 
included a licensed use or not. Of 1,017 remaining entries, the use of Convenia complied with 
the UK datasheet in 710 (69.8%) entries, comprising 553 skin entries and 157 urinary entries. 
Non-datasheet indications were described in the remaining 307 (30.2%) of 1,017 entries.  
 
DISCUSSION 
This study reveals a degree of responsible use of Convenia in the vet-visiting population of 
cats assessed. Most entries (69.8%) complied with the UK Convenia datasheet and so were 
licenced uses. However, other non-licenced uses of Convenia were described (30.2%). Since 
some uses could not be determined due to lack of information in clinical notes, the percentage 
of licensed uses may actually be greater.  
It is widely accepted that the veterinary profession must be proactive in its approach to 
AMR10. Although this study demonstrated a median prescribed dose of Convenia that 
complied with the data sheet, there was a wide range. Possible explanations for incorrect 
dosing included rounding of weight and incorrect estimations of weight, of concern if used to 
prescribe an antimicrobial with a specific dose described in the datasheet. A limitation of 
weight assessment in this study is that some weights were obtained from tabulated data and 
some from the clinical notes, and the accuracy of these is not known.  
One of the most remarkable findings was the low number of entries that recorded 
microbiological evaluation and visualisation of the purulent material was most frequently 
cited method of microbiological evaluation. Purulent material can be sterile, e.g. injection site 
reaction; so it may be wrong to assume microbial infection whenever there is purulent 
material. The lack of evidence of microbiological evaluation was most pertinent in the 
urinary body system entries where the presence of clinical signs associated with urinary 
disease may not necessarily indicate a UTI. Several conditions can cause FLUTD that may or 
may not have a bacterial component; a bacterial UTI is more commonly seen in senior and 
geriatric patients with comorbidities (e.g. chronic kidney disease, diabetes mellitus, 
hyperthyroidism)15 whereas younger male cats are most commonly diagnosed with idiopathic 
cystitis, a sterile condition16. Interestingly, half of urinary entries that received Convenia in 
this current study were less than ten years of age. A lack of confirmed diagnosis could lead to 
misuse of antimicrobials9.  
It is recognised that obtaining a urine sample for C&S is not appropriate or possible in every 
urinary case presented in a consultation, considering how difficult this can be in cats with 
cystitis and small bladders. However, where urine samples are obtained, the use of 
antimicrobials based solely on the results obtained on urinary dipsticks is of interest. The 
presence of positive changes for blood, protein and leucocytes does not infer bacterial 
infection and it is widely accepted that urinary dipstick leucocyte readings are unreliable in 
feline patients; urine cytology is more sensitive and specific for infection17. This study 
suggests that urine cytology is an under-utilised diagnostic tool that could provide valuable 
information to guide treatment. 
In this study there was lack of evidence of recorded reasons in clinical notes for use of 
Convenia over alternative antimicrobials (88% entries had no reason given). This may be a 
limitation of the study as justification may have been discussed with an owner and not 
recorded in the clinical notes. Additionally, from the clinical notes, it was not clear if each 
consultation was an initial or repeat consultation and therefore we were unable to ascertain 
whether Convenia had been used as a first line or second line antimicrobial. It is 
acknowledged that Convenia is a unique veterinary product as a broad spectrum long-acting 
injectable antibiotic and hugely useful where compliance is an issue18; however, for the 
purpose of trying to reduce AMR, this class of antimicrobial should be prescribed prudently9. 
Indeed, it has been suggested that for pyoderma Convenia should only be prescribed as a first 
line antimicrobial where there is concern about compliance or difficulty with oral 
administration19. For confirmed, uncomplicated UTIs International Society for Companion 
Animal Infectious Diseases guidelines recommend a seven-day course of amoxicillin or 
trimethoprim-sulphonamides20. Veterinarians have a responsibility to demonstrate an 
understanding of appropriate antimicrobial use and reasons for choosing one treatment plan 
over another. Additionally, an important aspect of antimicrobial stewardship is maximising 
the use of alternative management options such as topical treatments, effective lavage and 
debridement of infected material, providing symptomatic relief, e.g. from pruritus and 
inflammation. Antimicrobials are not indicated in sterile idiopathic cystitis and treatment 
should focus on stress management, environmental enrichment and weight management. 
Furthermore it is important to consider whether use of antimicrobials could be avoided or 
reduced (in duration or spectrum).  
Future studies could include specific questionnaires for the prescribing veterinarian about 
reasons for use of their treatment choice over alternative antimicrobials or actions. This study 
supports previous findings that antimicrobials are often prescribed without documented 
confirmation of infection21 and in the case of third generation cephalosporins, frequently 
without documented adequate justification. 
Manual assessment and interpretation of clinical notes introduces a possibility of human 
error, especially where over 1,000 entries are viewed. However, this number of entries 
minimises variation on interpretation and analysis of patterns. Beyond the scope of this 
current study, future data analysis could include a control group of cats presenting to 
practices at the same time, where no Convenia was given. 
We used data gathered from a small number of veterinary practices during pilot studies to 
establish the feasibility of SAVSNET methodologies to provide first opinion data on the use 
of antimicrobials in small companion animals. Thus, future analyses including data from a 
large number of practices currently recruited to SAVSNET would augment the current results, 
providing further understanding into antimicrobial prescribing practice in small animals.  
Whilst owners may prefer convenience over the idea of orally medicating, not being able to 
use oral antimicrobials limits vets prescribing abilities and introduces a potential risk factor 
for AMR. This study supports previous findings that further education of the public and the 
veterinary team is needed to promote responsible antimicrobial usage22. Focus is needed on 
educating owners about orally medicating their cats and only choosing this class of drug or 
duration of treatment where absolutely indicated. There are many resources available to a 
veterinarian to which an owner can be directed or which can be promoted within practice 
material e.g. www.youtube.com/user/iCatCare. Much work has occurred in human medicine 
to educate patients to trust doctors in the appropriate use of antimicrobials. We, as a 
profession, have an opportunity and responsibility to educate owners on appropriate 
antimicrobial use at the point of consultation and must routinely take the time to discuss 
antimicrobial stewardship. 
 CONCLUSION 
Most Convenia entries were in line with datasheet indications, however only a small 
percentage (12%) of entries included justification for prescribing Convenia over alternative 
antimicrobials. Most entries had no microbiological evaluation described and visualisation of 
purulent material was most cited.  
Our recommendation is that veterinary professionals consider better education of owners on 
how to successfully administer first line oral antimicrobials as an alternative to prescribing a 
long-acting broad spectrum injection and reserve use of Convenia for cases where bacterial 
infection has been confirmed and non-compliance excludes oral medication. SAVSNET data 
have been used to provide valuable insight into the use of therapeutics in veterinary practice. 
We would encourage information relevant to decision making to be recorded in individual 
animal health records. This will further increase the use of electronic health records as a 
valuable tool to monitor both locally and at scale the use of important therapeutics like 
antimicrobials. This study also suggests that further education of the veterinary team is 
needed to continue to promote responsible antimicrobial usage. 
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Table 1. Frequency of entries classified by Body System treated from SAVSNET database 
for all valid entries (1,148) for cefovecin/Convenia use. 
 
Body System treated Frequency Percent (%) 
Skin 553 48.2 
Urinary 157 13.7 
Respiratory 112 9.8 
Unclassified* 103 9.0 
Oral including dental 101 8.8 
Musculoskeletal 41 3.6  
Multiple** 28 2.4  
Gastrointestinal including liver and pancreas 27 2.4  
Ocular 19 1.7  
Neurological 5 0.4  
Cardiovascular 2 0.2  
* Used if unclear which primary body system was being treated with Convenia due to lack of 
information in clinical notes. 
**Used if more than one body system was described and it was unclear which primary body 
system was being treated with Convenia.  
 
 
